ResMed - RMD Stock Forecast, Price & News

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

ResMed Price Performance

Shares of ResMed stock opened at $240.85 on Friday. ResMed has a twelve month low of $189.40 and a twelve month high of $301.34. The stock has a market capitalization of $35.23 billion, a P/E ratio of 45.36, a PEG ratio of 2.28 and a beta of 0.47. The company has a current ratio of 2.55, a quick ratio of 1.56 and a debt-to-equity ratio of 0.20. The business's fifty day moving average price is $219.87 and its 200 day moving average price is $226.14.

ResMed (NYSE:RMD - Get Rating) last issued its earnings results on Thursday, August 11th. The medical equipment provider reported $1.49 earnings per share for the quarter, beating analysts' consensus estimates of $1.48 by $0.01. ResMed had a return on equity of 26.91% and a net margin of 22.02%. The firm had revenue of $914.74 million for the quarter, compared to analysts' expectations of $912.53 million. During the same quarter last year, the firm earned $1.35 earnings per share. The firm's revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, research analysts anticipate that ResMed will post 5.75 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on RMD shares. Royal Bank of Canada raised ResMed from a "sector perform" rating to an "outperform" rating and increased their target price for the stock from $233.00 to $244.00 in a research note on Monday, June 6th. StockNews.com downgraded ResMed from a "buy" rating to a "hold" rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $264.80.

Insider Buying and Selling at ResMed

In other ResMed news, insider David Pendarvis sold 1,545 shares of the firm's stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $209.44, for a total value of $323,584.80. Following the transaction, the insider now directly owns 108,376 shares of the company's stock, valued at $22,698,269.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider David Pendarvis sold 1,545 shares of ResMed stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $209.44, for a total value of $323,584.80. Following the completion of the transaction, the insider now directly owns 108,376 shares in the company, valued at $22,698,269.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael J. Farrell sold 5,675 shares of ResMed stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $196.61, for a total value of $1,115,761.75. Following the completion of the transaction, the chief executive officer now owns 405,260 shares of the company's stock, valued at $79,678,168.60. The disclosure for this sale can be found here. Insiders have sold 29,160 shares of company stock valued at $6,327,758 over the last three months. 1.42% of the stock is owned by company insiders.